[
  {
    "nct_id": "NCT05668741",
    "brief_title": "A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)",
    "official_title": "A Phase 1/2 Dose Escalation Study Evaluating the Safety, and Tolerability and Efficacy of VX-522 in Subjects 18 Years of Age and Older With Cystic Fibrosis and a CFTR Genotype Not Responsive to CFTR Modulator Therapy",
    "overall_status": "RECRUITING",
    "start_date": "2023-02-27",
    "completion_date": "2025-03-31",
    "brief_summary": "The purpose of this study is to evaluate the safety, and tolerability and efficacy of VX-522 in participants 18 years of age and older with cystic fibrosis and a cystic fibrosis transmembrane conductance regulator (CFTR) genotype not responsive to CFTR modulator therapy.",
    "detailed_description": "No detailed description",
    "sponsor": "Vertex Pharmaceuticals Incorporated",
    "collaborators": [
      "Moderna, Inc"
    ],
    "conditions": [
      "Cystic Fibrosis"
    ],
    "interventions": [],
    "phases": [
      "PHASE1",
      "PHASE2"
    ],
    "study_type": "INTERVENTIONAL"
  }
]